Fate Therapeutics, Inc.
FATE
$2.44
-$0.06-2.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 60.28% | -5.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 60.28% | -5.11% | |||
| Cost of Revenue | -1.28% | 160.17% | |||
| Gross Profit | 4.70% | -188.01% | |||
| SG&A Expenses | -7.99% | -62.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.16% | -1.97% | |||
| Operating Income | 5.65% | 1.85% | |||
| Income Before Tax | 3.38% | 3.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.38% | 3.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.38% | 3.59% | |||
| EBIT | 5.65% | 1.85% | |||
| EBITDA | 5.74% | 1.56% | |||
| EPS Basic | 3.65% | 4.24% | |||
| Normalized Basic EPS | 3.63% | 0.85% | |||
| EPS Diluted | 3.65% | 4.24% | |||
| Normalized Diluted EPS | 3.63% | 0.85% | |||
| Average Basic Shares Outstanding | 0.31% | 0.66% | |||
| Average Diluted Shares Outstanding | 0.31% | 0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||